A provision in Alaska's HB195 removes a regulatory cost barrier for pharmacies—and could affect how your workforce accesses healthcare services.
Most Alaska manufacturers don't realize that a healthcare bill moving through the state legislature contains a provision that strips away fees and regulatory oversight for pharmacy collaborative practice agreements. Here's what that means for your business.
House Bill 195, titled "Pharmacists; Physician Associates," includes a buried provision in Section 4 (new AS 08.02.150(a)) that prohibits any Alaska state department or licensing board from charging pharmacists fees to enter into or operate under collaborative practice agreements. The same section strips those boards of authority to require approval of or regulate the scope of those agreements.
In plain terms: pharmacists can no longer be charged by the state to set up or maintain agreements that let them expand patient care services—and the state loses its ability to regulate how those agreements work.
The provision takes effect January 1, 2027.
If your company operates a workplace health clinic, occupational health program, or partners with a pharmacy to serve employee healthcare needs, this change affects the regulatory landscape and cost structure of those services.
Collaborative practice agreements let pharmacists provide services—medication therapy management, immunizations, chronic disease management—that traditionally required physician oversight. Removing state fees and approval requirements lowers the barrier for pharmacies to expand these services. For employers, that can mean:
Conversely, removing state regulatory oversight means less standardized review of what services pharmacists can offer under these agreements—which could create uncertainty about scope and liability depending on how your pharmacy partner interprets the change.
The provision is effective January 1, 2027. If you're planning workplace health initiatives or renegotiating pharmacy service agreements, that date marks when this new regulatory environment takes hold. Any fees currently charged by the state for these agreements will no longer apply after that date.
If your company uses or is considering pharmacy services that rely on collaborative practice agreements, review your current arrangements and ask your pharmacy partners whether they plan to expand services once the fee barrier drops in 2027. Understand what services they may add and how that affects your workplace health offerings.
If you're not currently using these services, this change is less immediately relevant—but it signals a broader shift toward pharmacy-led care in Alaska, which may eventually affect your health plan options or employee benefits.
The full text of HB195 is available through the Alaska Legislature website. A free, business-specific summary of healthcare regulatory changes affecting Alaska manufacturers is available through your local trade association.